Scope of this report: The report provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis
(IBM) and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and also key players involved in the therapeutics development for Inclusion Body Myositis
(IBM) and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects.
Inclusion Body Myositis
causes a gradual deterioration of muscle strength and can affect most limb muscles.
Abstract: We report an unusual case of a 51-year-old woman with inclusion body myositis
associated with celiac sprue and idiopathic thrombocytopenic purpura.
Inclusion body myositis
(IBM) is one of the most frequent types of acquired inflammatory myopathy, typically affecting white men older than 50 years.
Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis
Idiopathic inflammatory myopathies, comprising dermatomyositis, polymyositis and inclusion body myositis
, (1) represent the largest group of acquired and potentially treatable causes of skeletal muscle weakness.
It has also produced and released oncoretroviral vectors for future trials in graft-versus-host disease, inclusion body myositis
and autoimmune diseases.